Articles

Many cancer vaccines have been studied, but thus far the search has been unsuccessful. Results from a new study suggest that the combination of a messenger (mRNA)-based personalized cancer vaccine (known as RO7198457) plus the PD-L1 inhibitor atezolizumab (Tecentriq) shows promise for the treatment of advanced cancer. The results of the phase 1b clinical trial were presented at the 2020 AACR virtual annual meeting.

Value-based drug purchasing, better coordination of care delivery, and earlier institution of palliative care were among the measures to lower the cost of cancer care that were suggested during a panel discussion at the 2020 virtual National Comprehensive Cancer Network (NCCN) Oncology Policy Summit. The discussion was moderated by Clifford Goodman, PhD, Senior Vice President, Comparative Effectiveness Research, the Lewin Group.

Value-based or alternative payment models have yet to deliver the cost-savings in oncology hoped for when these models were proposed, said experts at the September 2020 National Comprehensive Cancer Network Oncology Policy Summit during a panel discussion on best practices for value-based agreements.

Uncertainty reigns in Washington with the upcoming election only weeks away. What can cancer care stakeholders expect from legislators and policymakers over the next several weeks, during the lame duck session, and in 2021?

The top priority for employers regarding their employees’ cancer care coverage is ensuring access to state-of-the-art care. Learn how employers are trying to close the gap between “typical” and “optimal” care.

Telling the story of the Oncology Care Model and its performance over the past 5 years through some of the best-performing practices.

On October 8, 2020, the Berkeley Research Group published a report showing that contract pharmacy participation in the 340B Drug Pricing Program grew by 4228% between 2010, when the Health Resources and Services Administration expanded the contract pharmacy program, and 2020. A week later, on October 16, 2020, a variety of stakeholders in the 340B program—covered entities, contract pharmacies, pharmaceutical manufacturers, and outside tech consultants—participated in an intense discussion of contract pharmacy growth, newly imposed manufacturer audit requirements, and ways to return 340B to its original purpose of spreading scarce federal resources and serving vulnerable patients.

The AVBCC Summit kicks off tomorrow with “Washington Perspectives on Cancer Care.” The first of 45 sessions begins promptly at 8:00 am with a diverse combination of industry experts discussing the current and prospective policy and legislative initiatives that will impact cancer care in the near future given the pending election. With the current state of the country, the goal of this session is to help separate the “noise” from reality.

Cranbury, NJ – The WEBside Chat is a dynamic take on the fireside chat. This award-winning format will be utilized at the 10th Association for Value-Based Cancer Care (AVBCC) Summit and Educational Program starting October 13 and running for 10 weeks. Each 90-minute session is focused on one of more than 30 topics currently affecting the cancer care ecosystem. Each session is packed with high-octane, unfiltered discussion; real-time topics; and balanced opinions by some of the top leaders in the cancer care continuum.

The Association for Value-Based Cancer Care (AVBCC) is proud to announce a jam-packed agenda for the 2020 Summit. This year’s summit features the who’s who in the cancer care ecosystem in an award winning WEBside chat setting. The summit consists of over 30, 90-minute sessions, approximately 5 days a week for 10 weeks, featuring top influencers, future trends, balanced opinions, real-time, real-world information, and unfiltered discussions from over 150 faculty.